Update on renin-angiotensin-aldosterone blockade in heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 11, Issue 6, 2009, Pages 455-466

  Greenberg, Barry ^a   Kim, Young Sin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; FOSINOPRIL; HORMONE RECEPTOR BLOCKING AGENT; IRBESARTAN; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL SUCCINATE; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; TACROLIMUS; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

CLINICAL TRIAL; CONFUSION; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IMPOTENCE; LABORATORY TEST; LETHARGY; LIBIDO DISORDER; LOW DRUG DOSE; MASTALGIA; MENSTRUAL IRREGULARITY; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT MONITORING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMNOLENCE; ST SEGMENT ELEVATION; SYSTOLIC DYSFUNCTION; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 70449495630     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0048-y     Document Type: Review

References (41)

1. M.A. Pfeffer E. Braunwald L.A. Moyle, et al. 1992 Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N Engl J Med 327 669 677 1386652
2. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993, 342:821-828.
3. L. Kober C. Torp-Pederesen J.E. Carlsen, et al. 1995 A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group N Engl J Med 333 1670 1676 10.1056/ NEJM199512213332503 7477219 (Pubitemid 26001955)
4. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429-1435.
5. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325:293-302.
6. M.A. Pfeffer E. Braunwald L.A. Moye, et al. 1992 Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators N Engl J Med 327 685 691
7. D.N. Sharpe J. Murphy R. Coxon, et al. 1984 Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study Circulation 70 271 278 6329547
8. B. Greenberg M.A. Quinones C. Koilpillai, et al. 1995 Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy Circulation 91 2573 2581 7743619
9. P. Jong S. Yusuf M.F. Rousseau, et al. 2003 Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study Lancet 361 1843 1848 10.1016/S0140-6736(03)13501- 5 12788569 (Pubitemid 36645177)
10. J.G. Cleland M. Tendera J. Adamus, et al. 2006 The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur Heart J 27 2338 2345 10.1093/eurheartj/ehl250 16963472 (Pubitemid 44453578)
11. S.A. Hunt W.T. Abraham M.H. Chin, et al. 2005 ACC/AHA 2005 Guideline for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 112 e154 e235 10.1161/CIRCULATIONAHA.105.167586 16160202
12. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J 1998, 19:481-489.
13. J.N. Nanas G. Alexopoulos M.I. Anastasiou-Nana, et al. 2000 Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study J Am Coll Cardiol 36 2090 2095 10.1016/S0735-1097(00)01025-1 11127445
14. M. Packer P.A. Poole-Wilson P.W. Armstrong, et al. 1999 Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group Circulation 100 2312 2318 10587334
15. Z.H. Israili W.D. Hall 1992 Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology Ann Intern Med 117 234 242 1616218
16. K.S. Woo M.G. Nicholis 1995 High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese Br J Clin Pharmacol 40 141 144 8562296
17. R. Latini S. Masson I. Anand, et al. 2002 Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT) Circulation 106 2454 2458 10.1161/01.CIR.0000036747.68104.AC 12417542 (Pubitemid 35278801)
18. K. Dickenstein J. Kjekshus OPTIMAAL Steering Committee of the OPTIMAAL Study Group 2002 Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan Lancet 360 752 760 10.1016/S0140-6736(02)09895-1 (Pubitemid 35247704)
19. M.A. Pfeffer J.J. McMurray E.J. Velazquez, et al. 2003 Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 1893 1906 10.1056/NEJMoa032292 14610160 (Pubitemid 37409706)
20. C.B. Granger J.J. McMurray S. Yusuf, et al. 2003 Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 772 776 10.1016/S0140-6736(03)14284-5 13678870 (Pubitemid 37093917)
21. V.C. Lee D.C. Rhew M. Dylan, et al. 2004 Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction Ann Intern Med 141 693 704 15520426
22. K. Dickstein P. Chang R. Willenheimer, et al. 1995 Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure J Am Coll Cardiol 26 438 445 10.1016/0735-1097(95)80020-H 7608448
23. B. Pitt P.A. Poole-Wilson R. Segal, et al. 2000 Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II Lancet 355 1582 1587 10.1016/S0140-6736(00)02213-3 10821361
24. J.J. McMurray J. Ostergren K. Swedberg, et al. 2003 Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 761 767
25. S. Yusuf M.A. Pfeffer K. Swedberg, et al. 2003 Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 777 781 10.1016/S0140-6736(03) 14285-7 13678871 (Pubitemid 37093918)
26. B.M. Massie P.E. Carson J.J. McMurray, et al. 2008 Irbesartan in patients with heart failure and preserved ejection fraction N Engl J Med 359 2456 2467 10.1056/NEJMoa0805450 19001508
27. B. Pitt F. Zannad W.J. Remme, et al. 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 709 717 10.1056/NEJM199909023411001 10471456 (Pubitemid 29407370)
28. M. Cicoira L. Zanolla A. Rossi, et al. 2002 Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure J Am Coll Cardiol 40 304 310 10.1016/S0735-1097(02)01965-4 12106936 (Pubitemid 34756292)
29. F.J. Ramires A. Mansur O. Coelho, et al. 2000 Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy Am J Cardiol 85 1207 1211 10.1016/S0002-9149(00)00729-3 10802002 (Pubitemid 30232815)
30. B. Pitt W. Remme F. Zannad, et al. 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309 1321 10.1056/NEJMoa030207 12668699 (Pubitemid 36384098)
31. T. Tsutamoto A. Wada K. Maeda, et al. 2001 Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure J Am Coll Cardiol 37 1228 1233 10.1016/S0735-1097(01)01116-0 11300427 (Pubitemid 32295579)
32. U. Dahlstrom E. Karlsson 1993 Captopril and spironolactone therapy for refractory congestive heart failure Am J Cardiol 71 29A 33A 10.1016/0002- 9149(93)90242-5 8422001
33. B. Bozkurt I. Agoston A.A. Knowlton 2003 Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines J Am Coll Cardiol 41 211 214 10.1016/S0735-1097(02)02694-3 12535810 (Pubitemid 36092186)
34. D.N. Juurlink M.M. Mamdani D.S. Lee, et al. 2004 Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 543 551 10.1056/NEJMoa040135 15295047 (Pubitemid 39025171)
35. D.T. Ko D.N. Juurlink M.M. Mamdani, et al. 2006 Appropriateness of spironolactone prescribing in heart failure patients: a population-based study J Card Fail 12 205 210 10.1016/j.cardfail.2006.01.003 16624686
36. J.E. Sealey J.H. Laragh 2007 Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness Am J Hypertens 20 587 597 10.1016/j.amjhyper.2007.04.001 17485026 (Pubitemid 46678721)
37. J.J. McMurray B. Pitt R. Latini 2008 Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure Circ Heart Fail 1 17 24 10.1161/CIRCHEARTFAILURE.107.740704 19808266
38. M. Iwata R.T. Cowling D. Gurantz 2005 Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects Am J Physiol Heart Circ Physiol 289 H2356 H2363 10.1152/ajpheart.00317. 2005 16024575 (Pubitemid 41698543)
39. K. Yamamoto M. Ohishi T. Katsuya 2006 Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II Hypertension 47 718 726 10.1161/01.HYP.0000205833.89478.5b 16505206 (Pubitemid 43740244)
40. S. Epelman W.H. Tang S.Y. Chen 2008 Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system J Am Coll Cardiol 52 750 754 10.1016/j.jacc.2008.02.088 18718423
41. R.E. Schmieder 2005 Mechanisms for the clinical benefits of angiotensin II receptor blockers Am J Hypterens 18 720 730 10.1016/j.amjhyper.2004.11.032 (Pubitemid 40692442)